Menu
Spearheaded the commercialization of a new corneal wound healing contact lens, treating over 1,000,000 patients and securing early-stage financing.
With 30 years in ophthalmic devices and pharmaceuticals, he introduced glaucoma shunts and amniotic membrane technologies to the US market.
An expert of the diagnosis and treatment of macular degeneration, glaucoma, and diabetes, Dr. Gelb is experienced in the evaluation and fitting of specialty contact lenses.
Diopter Technologies holds a strong intellectual property foundation. They are inviting investors and collaborators to help reshape the future of ophthalmology and improve the lives of millions of patients globally.